Remedy Robotics Secures $62 Million to Revolutionize Cardiovascular Care with Robotics
In an exciting development for healthcare innovation,
Remedy Robotics, Inc. has announced the successful raising of
$62 million in Series B funding. This prominent healthcare and physical AI company is dedicated to developing cutting-edge robotic systems that enhance cardiovascular care and endovascular interventions. With this new influx of capital, Remedy aims to expand access to life-saving procedures, ensuring a brighter future for patients worldwide, regardless of their location.
Founded with a vision to deliver immediate and flawless robotic care, Remedy is focused on tackling the urgent need for efficient cardiovascular interventions. According to
Dr. David Bell, CEO and Co-founder of Remedy Robotics, the funding will facilitate crucial clinical trials in collaboration with the
University of California, as well as advance their applications for FDA approval related to neurovascular intervention. By deploying its prototype
N1 Systems across a robust network of clinical partners—including engagements with the
SVIN Mission Thrombectomy and the
Australian Stroke Alliance—Remedy is setting the stage for transformative healthcare solutions.
Endovascular intervention stands as the leading treatment method for stroke and numerous cardiovascular emergencies. However, a significant challenge persists: access to such specialized care is often available only in a limited number of hospitals. This reality can be fatal, with many patients experiencing delays in treatment. To address these critical time-sensitive conditions, Remedy Robotics draws on advanced artificial intelligence. The N1 System, currently in development, is designed to conduct endovascular procedures autonomously or remotely, thereby enhancing accessibility and minimizing complications.
Leading the Series B funding round was
DCVC, with additional investment from new partners such as
UC Investments and
Skip Capital, as well as existing investors like
Blackbird and
KdT Ventures. This financial support underscores the potential of Remedy to expand its innovative technologies across the globe.
James Hardiman, General Partner at DCVC, expressed enthusiasm about supporting Remedy, noting their commitment to not just innovation but addressing real-world healthcare challenges.
The company is rapidly finalizing its
N1 System—an advanced AI-enabled platform that integrates machine learning for preoperative imaging analysis, simultaneous 3D-2D image registration, and full robotic execution of endovascular treatments. Remedy's current reach includes over
100 hospitals across the globe, making it one of a few organizations pioneering the application of robotics in real-world medical settings. Its recent milestone was the completion of the world's first remote neurointerventional procedures using the N1 System, showcasing the potential of this technology.
Jake Sganga, Chief Technology Officer and Co-founder, highlighted that this funding will empower their teams to further innovate the N1 System, emphasizing their shared excitement for continued collaboration with the University of California in preparation for pivotal trials.
As cardiovascular diseases continue to be the leading cause of death worldwide—claiming
nearly 20 million lives annually—the urgency for effective treatment methods is paramount. Unfortunately, only about
2.8% of eligible stroke patients globally have access to these critical endovascular procedures. Remedy’s technological advancements aim to bridge this access gap, empowering providers to deliver expert-level care wherever it is needed, from major cities to rural regions underserved by existing medical infrastructure.
Looking ahead, Remedy Robotics is devoted to enhancing the overall standard of care across the cardiovascular continuum, impacting outcomes from diagnosis through to recovery and surveillance. Their mission is clear: to make innovative, immediate cardiovascular intervention available to all, whether in
San Francisco, rural
Arkansas, or even
Lagos, Nigeria, where such access is typically absent.
Despite the great promise shown by the N1 System, it remains under development and is currently unavailable for clinical use. Nonetheless, Remedy Robotics stands at the forefront of health tech innovation, offering hope for patients who might otherwise face debilitating conditions due to lack of timely, effective care.
For more information about their pioneering work, visit
Remedy Robotics.